MetaFines
Seongnam
About MetaFines
MetaFines is a biopharma firm that creates anticancer medications with the goal of preventing the spread of cancer. By extending and reconfiguring the indications of off-label medications for terminal tumors, the company creates minimal anticancer pharmaceuticals. It also provides subcutaneous injections and therapies, allowing patients to fight cancer and enhance their standard of living with cancer metabolism. The company develops ow-toxic medicines for metabolic cancer. This low-toxic metabolic anti-cancer agent is distinguished by being created so that metabolic anti-cancer agents that limit cell growth but operate via various pathways can work in concert with one another.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $23.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2022)
- Website: metafines.com
- Phone: +82 031-755-5569
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/metafines-54985 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.